Efficacy and safety of rezivertinib (BPI-7711) in patients with locally advanced or metastatic/recurrent EGFR T790M-mutated NSCLC: A phase IIb, multicenter, singlearm, open-label study
机构：[1]The First Hospital of Shanxi Medical University, Taiyuan, China[2]West China Hospital of Sichuan University, Chengdu, China四川大学华西医院[3]Department of Oncology, The Henan Province Hospital of Zhengzhou University, Zhengzhou, China[4]Sichuan Cancer Hospital & Institute, Chengdu, China四川省肿瘤医院[5]Zhejiang Cancer Hospital, Hangzhou, China浙江省肿瘤医院[6]Hunan Cancer Hospital, Changsha, China[7]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China[8]Anhui Provincial Hospital, Hefei, China[9]Affiliated Hospital of Guangdong Medical University, Zhanjiang, China[10]The Second Affiliated Hospital of Army Medical University, PLA, Chongqing, China[11]Department of Respiration, Harbin Medical University Cancer Hospital, Harbin, China[12]Linyi Cancer Hospital, Linyi, China[13]Central Hospital Affiliated to Shandong First Medical University, Jinan, China[14]Peking University Cancer Hospital, Beijing, China[15]The Second Affiliated Hospital of Xingtai Medical College, Xingtai, China[16]People’s Hospital of Deyang City, Deyang, China[17]BetaPharma, Princeton, NJ[18]Beta Pharma (Shanghai) Co., Ltd., Shanghai, China[19]Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
第一作者机构：[1]The First Hospital of Shanxi Medical University, Taiyuan, China[2]West China Hospital of Sichuan University, Chengdu, China[3]Department of Oncology, The Henan Province Hospital of Zhengzhou University, Zhengzhou, China[4]Sichuan Cancer Hospital & Institute, Chengdu, China[5]Zhejiang Cancer Hospital, Hangzhou, China[6]Hunan Cancer Hospital, Changsha, China[7]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China[8]Anhui Provincial Hospital, Hefei, China[9]Affiliated Hospital of Guangdong Medical University, Zhanjiang, China[10]The Second Affiliated Hospital of Army Medical University, PLA, Chongqing, China[11]Department of Respiration, Harbin Medical University Cancer Hospital, Harbin, China[12]Linyi Cancer Hospital, Linyi, China[13]Central Hospital Affiliated to Shandong First Medical University, Jinan, China[14]Peking University Cancer Hospital, Beijing, China[15]The Second Affiliated Hospital of Xingtai Medical College, Xingtai, China[16]People’s Hospital of Deyang City, Deyang, China[17]BetaPharma, Princeton, NJ[18]Beta Pharma (Shanghai) Co., Ltd., Shanghai, China[19]Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
推荐引用方式(GB/T 7714)：
Wu Shiman,Wang Ke,Cang Shundong,et al.Efficacy and safety of rezivertinib (BPI-7711) in patients with locally advanced or metastatic/recurrent EGFR T790M-mutated NSCLC: A phase IIb, multicenter, singlearm, open-label study[J].JOURNAL OF CLINICAL ONCOLOGY.2022,40(16):
APA：
Wu, Shiman,Wang, Ke,Cang, Shundong,Yao, Wenxiu,Fan, Yun...&Shi, Yuankai.(2022).Efficacy and safety of rezivertinib (BPI-7711) in patients with locally advanced or metastatic/recurrent EGFR T790M-mutated NSCLC: A phase IIb, multicenter, singlearm, open-label study.JOURNAL OF CLINICAL ONCOLOGY,40,(16)
MLA：
Wu, Shiman,et al."Efficacy and safety of rezivertinib (BPI-7711) in patients with locally advanced or metastatic/recurrent EGFR T790M-mutated NSCLC: A phase IIb, multicenter, singlearm, open-label study".JOURNAL OF CLINICAL ONCOLOGY 40..16(2022)
医学